Malignant meningioma: A clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry

American Journal of Clinical Pathology

Volumn 105, Issue 6, 1996, Pages 719-726

  Prayson, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Malignant meningioma; Meningioma; MIB1 antibody; p53 protein

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN BIOPSY; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HEADACHE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; MALE; MENINGIOMA; MITOSIS INDEX; MUSCLE WEAKNESS; PARESTHESIA; PRIORITY JOURNAL; SKIN METASTASIS; VISUAL IMPAIRMENT;

EID: 0029893237     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/105.6.719     Document Type: Article

References (52)

1. Kleihues P, Burger PC, Scheithauer BW. World Health Organization Histological Typing of Tumours of the Central Nervous System. ed 2. New York: Springer-Verlag, 1993, p 37.
2. Cattoretti G, Becker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin xenons. J Pathol 1992;168:357-363.
3. McCormick D, Chong H, Hobbs C, et al. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB-1. Histopathology 1993;22:355-360.
4. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: A study with MIB1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:41-54.
5. Ohta M, Iwaki T, Kitamoto T, Takeshita I, Tateishi J, Fukui M. MIB1 staining index and scoring of histologic features in meningioma: Indicators for the prediction of biologic potential and postoperative management. Cancer 1994;74:3176-3189.
6. Karamitopoulou E, Perentes E, Diamantis I. p53 protein expression in central nervous system tumors: An immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol 1993;85:611-616.
7. Chozick BS, Weicker ME, Pezullo JC, et al. Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 1993;73:406-415.
8. von Deimling A, Eibl RH, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992;52:2987-2990.
9. Haapasalo H, Isola J, Sallinen P, Kalimo H, Helin H, Rantala I. Aberrant p53 expression in astrocytic neoplasms of the brain: Association with proliferation. Am J Pathol 1993;142:1347-1351.
10. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994;53:11-21.
11. Ellison DW, Lunec J, Gallagher PJ, Steart PV, Jaros E, Gatter KC. Accumulation of wild-type p53 in meningiomas. Neuropathol Appl Neurobiol 1995;21:136-142.
12. Stoller JK, Kavuru M, Mehta AC, Weinstein CE, Estes ML, Gephardt GN. Intracranial meningioma metastatic to the lung. Cleve Clin J Med 1987;54:521-527.
13. Tubbs RR, Sheibani K. Immunohistology of lymphoproliferative disorders. Semin Diagn Pathol 1984;1:272-284.
14. Goldblum JR, Shannon R, Kaljiam EP, et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 1993;6:663-668.
15. de la Monte SM, Flickinger J, Linggood RM. Histopathologic features predicting recurrence of meningiomas following subtotal resection. Am J Surg Pathol 1986;10:836-843.
16. Skullerud K, Löken AC. The prognosis in meningiomas. Acta Neuropathol (Berl) 1974;29:337-344.
17. Jääkskeläinen J, Haltia M, Laasonen E, Wahlström T, Valtonen S. The growth rate of intracranial meningiomas and its relation to histology: An analysis of 43 patients. Surg Neurol 1985;24:165-172.
18. Jellinger K, Slowik F. Histological subtypes and prognostic problems in meningiomas. J Neurol 1975;208:279-298.
19. Deen HGJ, Scheithauer BW, Ebersold MJ. Clinical and pathological study of meningiomas of the first two decades of life. J Neurosurg 1982;56:317-322.
20. Jääkskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients. Surg Neurol 1986;26: 461-469.
21. Chan RC, Thompson GB. Morbidity, mortality and quality of life following a surgery for intracranial meningiomas. J Neurosurg 1984;60:52-60.
22. Maier H, Ofner D, Hittnair A, Kitz A, Budka H. Classic, atypical and anaplastic meningioma: Three histopathologic subtypes of clinical relevance. J Neurol Surg 1992;77:616-623.
23. Boker DK, Meurer H, Gullotta F. Recurring intracranial meningiomas: Evaluation of some factors predisposing for tumor recurrence. J Neurosurg Sci 1985;29:11-17.
24. Fabiani A, Trebini F, Favero M, Peres B, Palmucci L. The significance of atypical mitoses in malignant meningiomas. Acta Neuropathol (Berl) 1977;38:229-231.
25. Wong G, Harper C. Atypical meningiomas: Clinical pathological correlation. Aust N Z J Surg 1984;54:331-336.
26. Crompton MR, Gautier-Smith PC. The prediction of recurrence in meningiomas. J Neurol Neurosurg Psychiatry 1970;33:80-87.
27. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM. Atypical and malignant meningiomas: A clinicopathologic review. Neurosurgery 1993;33:955-963.
28. McLean CA, Jolley D, Cukier E, Giles G, Gonzales MF. Atypical and malignant meningiomas: Importance of micronecrosis as a prognostic indicator. Histopathology 1993;23:349-353.
29. Thomas HG, Dolman CC, Berry K. Malignant meningioma: Clinical and pathological feature. J Neurosurg 1981;55:929-934.
30. Miller DC. Predicting recurrence of intracranial meningiomas. A multivariate clinicopathologic model: Interim report of the New York University Medical Center Meningioma Project. Neurosurg Clin N Am 1994;5:193-200.
31. Karasick JL, Mullan SF. A survey of metastatic meningiomas. J Neurosurg 1974;39:206-209.
32. Miller DC, Ojemann RG, Proppe KH, McGinnis BD, Grillo HC. Benign metastasizing meningioma. J Neurosurg 1985;62:763-766.
33. Som PM, Sacher M, Strenger SW, Biller HF, Malis LI. "Benign" metastasizing meningioma. AJNR 1987;8:127-130.
34. Couldwell WT, Fankhauser H, de Tribolet N. Osseous metastases from a benign intraventricular meningioma: Case report. Acta Neurochir (Wien) 1992;117:195-199.
35. Ng THK, Wong MP, Chan KW. Benign metastasizing meningioma. Clin Neurol Neurosurg 1990;92:152-154.
36. Jääkskeläinen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: Radiology, surgery, radiotherapy and outcome. Surg Neurol 1986;25:233-242.
37. Burger PC, Scheithauer BW. Tumors of the central nervous system. In: Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology, 1994, pp 259-286.
38. Ludwin SK, Rubinstein LJ, Russell DS. Papillary meingioma: A malignant variant of meningioma. Cancer 1975;36:1363-1373.
39. Pasquier B, Gasnier F, Pasquier D, Keddari E, Morens A. Couderc P. Papillary meningioma: Clinicopathologic study of seven cases and review of the literature. Cancer 1986;58:299-305.
40. Zorludemir S, Scheithauer BW, Hirose T, Van Houten C, Miller G, Meyer FB. Clear cell meningioma: A clinicopathologic study of a potentially aggressive variant of meningioma. Am J Surg Pathol 1995;19:493-505.
41. Salmon I, Kiss R, Levivier M, Remmelink M, Pasteels J-L, Brotchi J, Flament-Durand J. Characterization of nuclear DNA content, proliferation index, and nuclearr size in a series of 181 meningiomas, including benign primary, recurrent, and malignant tumors. Am J Surg Pathol 1993;17:239-247.
42. Kunishio K, Ohmoto T, Matsuhisa T, Maeshiro T, Furuta T, Matsumoto K. The significance of nucleolar organizer region (Ag-NOR) score in predicting meningioma recurrence. Cancer 1994;73:2200-2205.
43. Ahyai A, Spaar FW. DNA and prognosis of meningiomas. A comparative cytological and fluorescence: Cytophotometrical study of 71 tumours. Acta Neurochir 1987;87:119-128.
44. Spaar FW, Ahyai A, Blech M. DNA-fluorescence cytometry and prognosis (grading) of meningiomas: A study of 104 surgically removed tumors. Neurosurg Rev 1987;10:35-39.
45. Hoshino T, Nagashima T, Murovic JA, et al. Proliferative potential of human meningiomas of the brain: A cell kinetics study with bromodeoxyuridine. Cancer 1986;58:1466-1472.
46. Cho KG, Hoshino T, Nagashima T, et al. Prediction of tumor doubling time in recurrent meningiomas: Cell kinetics studies with bromodeoxyuridine labeling. J Neurosurg 1986;65:790-794.
47. Iwaki T, Takeshita I, Fukui M, et al. Cell kinetics of the malignant evolution of meningothelial meningiomas. Acta Neuropathol 1987;74:243-247.
48. Roggendorf W, Schuster T, Peiffer J. Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropathol (Berl) 1987;73:363-364.
49. Hsu DW, Pardo FS, Efird JT, Linggood RM, Hedley-Whyte ET. Prognostic significance of proliferative indices in meningiomas. J Neuropathol Exp Neurol 1994;53:247-255.
50. Lee KS, Hoshino T, Rodriguez LA, Bederson J, Davis RL, Wilson CB. Bromodeoxyuridine labeling study of intracranial meningiomas: Proliferative potential and recurrence. Acta Neuropathol 1990;80:311-317.
51. Zimmer C, Gottschalk J, Cervos-Navarro J, Martin H, Beil M, Jautzke G. Proliferating cell nuclear antigen (PCNA) in atypical and malignant meningiomas. Path Res Pract 1992;188:951-958.
52. Ellison DW, Lunec J, Gallagher PJ, Steart PV, Jaros E, Gatter KC. Accumulation of wild-type p53 in meningiomas. Neuropathol Appl Neurobiol 1995;21:136-142.